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Abstract
The contractile response of the heart can be altered by disease-related protein modifications to numerous contractile
proteins. By utilizing an IAANS labeled fluorescent troponin C, TnC
T53C
IAANS, we examined the effects of ten disease-related
troponin modifications on the Ca
2+ binding properties of the troponin complex and the reconstituted thin filament. The
selected modifications are associated with a broad range of cardiac diseases: three subtypes of familial cardiomyopathies
(dilated, hypertrophic and restrictive) and ischemia-reperfusion injury. Consistent with previous studies, the majority of the
protein modifications had no effect on the Ca
2+ binding properties of the isolated troponin complex. However, when
incorporated into the thin filament, dilated cardiomyopathy mutations desensitized (up to 3.3-fold), while hypertrophic and
restrictive cardiomyopathy mutations, and ischemia-induced truncation of troponin I, sensitized the thin filament to Ca
2+
(up to 6.3-fold). Kinetically, the dilated cardiomyopathy mutations increased the rate of Ca
2+ dissociation from the thin
filament (up to 2.5-fold), while the hypertrophic and restrictive cardiomyopathy mutations, and the ischemia-induced
truncation of troponin I decreased the rate (up to 2-fold). The protein modifications also increased (up to 5.4-fold) or
decreased (up to 2.5-fold) the apparent rate of Ca
2+ association to the thin filament. Thus, the disease-related protein
modifications alter Ca
2+ binding by influencing both the association and dissociation rates of thin filament Ca
2+ exchange.
These alterations in Ca
2+ exchange kinetics influenced the response of the thin filament to artificial Ca
2+ transients
generated in a stopped-flow apparatus. Troponin C may act as a hub, sensing physiological and pathological stimuli to
modulate the Ca
2+-binding properties of the thin filament and influence the contractile performance of the heart.
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Introduction
The heart is a highly dynamic organ that can regulate both
its contractile strength and speed to accommodate the demands
of the body. Numerous cardiac diseases adversely alter the
heart’s ability to properly maintain its performance [1]. It is
well established that aberrant intracellular Ca
2+ signaling is
associated with systolic and diastolic cardiac dysfunctions [2,3].
Cardiac diseases may also alter how the heart responds to the
Ca
2+ signal [4]. For instance, numerous reports have demon-
strated that myofilament Ca
2+ sensitivity is affected by
cardiomyopathy associated protein mutations, truncations and
post-translational modifications [5,6,7,8]. Thus, contractile
dysfunctions may be caused by both altered intracellular Ca
2+
signaling and abnormal myofilament responsiveness to the Ca
2+
signal [4,9].
Troponin C (TnC) is the myofilament Ca
2+ sensor in cardiac
muscle responsible for translating the intracellular Ca
2+ signal
into mechanical force [10]. The Ca
2+ sensitivity of TnC can be
modulated by multiple factors, including its interactions with
other myofilament proteins, post-translational modifications of
the myofilament, as well as cardiac disease-related protein
modifications [11,12,13,14]. In this regard, TnC is not just a
passive element that transmits the Ca
2+ signal. Instead, it may
act as a central hub that integrates information from the
myofilament (beneficial or maligned) and adjusts its Ca
2+
binding properties to regulate cardiac muscle mechanics [15].
While it is clear that myofilament disease-related protein
modifications can alter the steady-state Ca
2+ sensitivity of TnC,
much less is known regarding their effects on TnC’s Ca
2+
exchange kinetics [16,17,18]. The kinetics of Ca
2+ exchange with
TnC may be even more significant to how the heart performs since
the heart is dynamic and does not function in a static steady-state.
Furthermore, it is the kinetics of Ca
2+ exchange with TnC,
including the rate of Ca
2+ association to and dissociation from
TnC that determine its steady state Ca
2+ sensitivity. The rate of
Ca
2+ association is 3 to 4 orders of magnitude faster than the rate
of Ca
2+ dissociation, and considered diffusion controlled (for
review see [15]). Thus, it is generally assumed that changes in the
steady-state Ca
2+ sensitivity of TnC are caused exclusively by
modulating the rate of Ca
2+ dissociation. However, our previous
studies suggest the rate of Ca
2+ association to TnC can also be
altered [19,20].
In this work, disease-related protein modifications of troponin
I (TnI) and troponin T (TnT) were selected to systematically
study their effects on Ca
2+ binding and exchange with the
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cently labeled TnC. The protein modifications include five
dilated cardiomyopathy (DCM) mutations (TnI K36Q, TnT
R141W, TnT R131W, TnT R205L, and TnT DK210), two
hypertrophic cardiomyopathy (HCM) mutations (TnI S166F
and TnT R92Q), two restrictive cardiomyopathy (RCM)
mutations (TnI D190H and TnI R192H), and an ischemia-
induced truncation of TnI (residues 1-192). These protein
modifications represent a broad spectrum of diseases that
change the steady-state Ca
2+ sensitivity of the actomyosin
ATPase activity and/or force generation [12,13,21,22]. More
importantly, some of these protein modifications also alter the
kinetics and amplitude of cardiac muscle contraction and/or
relaxation [23,24]. We demonstrate that these disease associated
protein modifications adversely altered steady-state Ca
2+ binding
to TnC by influencing both its Ca
2+ association and dissociation
rates on the thin filament (with almost no effect when measured
in the isolated Tn complex). These results suggest that TnC acts
as a central hub on the thin filament by sensing pathological
stimuli to alter cardiac contractile properties.
Materials and Methods
Materials
Phenyl-Sepharose CL-4B, Tween-20, and EGTA were pur-
chased from Sigma Chemical Co. (St. Louis, MO). IAANS and
phalloidin were purchased from Invitrogen (Carlsbad, CA). Affi-
Gel 15 affinity media was purchased from Bio-Rad (Hercules,
CA).
Protein Mutagenesis
The pET3a plasmid encoding human cardiac TnC was a
generous gift from Dr. Lawrence Smillie (University of Alberta,
Canada). The pET3a plasmids encoding human cardiac TnI and
TnT were graciously provided by Dr. James Potter (University of
Miami, FL). TnC, TnI and TnT mutants were constructed from
their respective pET3a plasmids using the primer-based Quik-
Change Site-Directed Mutagenesis Kit (Stratagene, Santa Clara,
CA) as previously described [11]. The mutations were confirmed
by DNA sequence analysis at an on-site molecular genetics core
facility.
Figure 1. Effect of disease-related protein modifications on the Ca
2+ sensitivity of the Tn complex. Panel A shows the Ca
2+ dependent
decreases in IAANS fluorescence for control TnT53C
IAANS (%), and the DCM mutants, TnI K36Q TnT53C
IAANS (?), TnT R131W TnT53C
IAANS (#), TnT R141W TnT53C
IAANS
(N), TnT R205L TnT53C
IAANS (&) and TnT DK210 TnT53C
IAANS (q) as a function of pCa. Panel B shows the Ca
2+ dependent decreases in IAANS fluorescence
for control TnT53C
IAANS (%), and the HCM mutants, TnT R92Q TnT53C
IAANS (.) and TnI S166F TnT53C
IAANS (m) as a function of pCa. Panel C shows the Ca
2+
dependent decreases in IAANS fluorescence for control TnT53C
IAANS (%), and the RCM mutants, TnI D190H TnT53C
IAANS (h) and TnI R192H TnT53C
IAANS (n)a sa
function of pCa. Panel D shows the Ca
2+ dependent decreases in IAANS fluorescence for control TnT53C
IAANS (%) and ischemic related truncated TnI (1-
192) TnT53C
IAANS ( ) as a function of pCa. The data sets were normalized individually for each mutant. All TnT53C
IAANS complexes consist of the full length
Tn subunits of TnC
T53C
IAANS, TnI and TnT, except for ischemic related truncated TnI (1-192). The disease related modification is either in TnI or TnT, in
either case, the other protein (TnT or TnI) was wild type. The Ca
2+ sensitivities were reported as a dissociation constant Kd, representing a mean of
three to four separate titrations 6 S.E.M.
doi:10.1371/journal.pone.0038259.g001
TnC, a Hub for the Thin Filament
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2+ binding properties of the Tn complex.
Protein Disease Subtype Tn complex Ca
2+ Kd (mM) Tn complex nH Tn complex Ca
2+ koff (/s)
Control – 0.6660.03 0.9060.02 40.860.4
TnI K36Q DCM 0.6860.07 0.9560.05 48.560.3*
TnT R141W DCM 0.7160.09 0.8760.04 39.360.3
TnT R131W DCM 0.960.2 0.8060.04 42.060.6
TnT R205L DCM 0.8060.06 0.8660.06 41.660.5
TnT DK210 DCM 0.6160.01 0.8660.01 40.760.5
TnT R92Q HCM 0.7360.06 0.8560.05 4062
TnI S166F HCM 0.4360.04* 0.9660.04 22.560.1*
TnI D190H RCM 0.6260.05 0.9560.04 40.360.4
TnI R192H RCM 0.67460.007 0.8960.03 41.260.6
TnI (1-192) Ischemia injury 0.5960.03 1.0060.07 42.060.8
Values marked with * are significantly different from their respective control values (p,0.05).
doi:10.1371/journal.pone.0038259.t001
Figure 2. Effect of disease-related protein modifications on the rate of Ca
2+ dissociation from the Tn complex. Panel A shows the time
courses of the increase in IAANS fluorescence as Ca
2+ was removed by EGTA from control TnT53C
IAANS, and the DCM mutants, TnI K36Q TnT53C
IAANS, TnT
R131W TnT53C
IAANS, TnT R141W TnT53C
IAANS, TnT R205L TnT53C
IAANS and TnT DK210 TnT53C
IAANS. Panel B shows the time courses of the increase in IAANS
fluorescence as Ca
2+ was removed by EGTA from control TnT53C
IAANS, and the HCM mutants, TnT R92Q TnT53C
IAANS and TnI S166F TnT53C
IAANS. Panel C shows
the time courses of the increase in IAANS fluorescence as Ca
2+ was removed by EGTA from control TnT53C
IAANS, and the RCM mutants, TnI D190H
TnT53C
IAANS and TnI R192H TnT53C
IAANS. Panel D shows the time courses of the increase in IAANS fluorescence as Ca
2+ was removed by EGTA from control
TnT53C
IAANS and ischemic related truncated TnI (1-192) TnT53C
IAANS. All TnT53C
IAANS complexes consist of the full length Tn subunits of TnC
T53C
IAANS, TnI and TnT,
except for ischemic related truncated TnI (1-192). The disease related modification is either in TnI or TnT, in either case, the other protein (TnT or TnI)
was wild type. Data traces (an average of 3 to 5 individual traces collected at least 10 times) were fit with a single exponential equation to calculate
the kinetic rates. The data traces have been staggered and normalized for clarity.
doi:10.1371/journal.pone.0038259.g002
TnC, a Hub for the Thin Filament
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The plasmid encoding human cardiac TnC was transformed
into E. coli BL21(DE3)pLysS cells (Novagen, San Diego, CA),
while the TnI and TnT plasmids were transformed into
Rosetta
TM(DE3)pLysS cells (Novagen, San Diego, CA). The
proteins were expressed and purified as previously described
[25].
Rabbit skeletal actin and bovine ventricular tropomyosin (Tm)
were purified from acetone powders as previously described
[26,27]. Fresh bovine cardiac muscle was purchased from The
Herman Falter Packing Company (Columbus, OH). All the
animal protocols and procedures were performed in accordance
with the National Institutes of Health Guidelines and approved by
the Institutional Laboratory Animal Care and Use Committee at
The Ohio State University.
Fluorescent Labeling
TnC
C35S,T53C,C84S (herein denoted as TnC
T53C) was labeled
with the environmentally sensitive thiol-reactive fluorescent probe
IAANS as previously described [25].
Reconstitution of Troponin Complexes and Regulated
Thin Filaments
The reconstituted Tn complexes and regulated thin filaments
were prepared as previously described [25]. All the Tn complexes
contain full length Tn subunits of recombinant human TnC
T53C
IAANS,
TnI (except for the truncated TnI (1-192)) and TnT.
Steady-State Fluorescence Measurements
All steady-state fluorescence measurements were performed
using a Perkin-Elmer LS55 spectrofluorimeter at 15uC. IAANS
fluorescence was excited at 330 nm and monitored at 450 nm as
microliter amounts of CaCl2 were added to 2 ml of each labeled
Tn complex (0.15 mM) in a titration buffer (200 mM MOPS (to
prevent pH changes upon addition of Ca
2+), 150 mM KCl, 2 mM
Figure 3. Effect of disease-related protein modifications on the Ca
2+ binding sensitivity of the thin filament. Panel A shows the Ca
2+
dependent increases in IAANS fluorescence for thin filament bound control TnT53C
IAANS (%), and the DCM mutants, TnI K36Q TnT53C
IAANS (w), TnT R131W
(#)TnT53C
IAANS, TnT R141W TnT53C
IAANS (N), TnT R205L TnT53C
IAANS (&) and TnT DK210 TnT53C
IAANS (q) as a function of pCa. Panel B shows the Ca
2+ dependent
increases in IAANS fluorescence for thin filament bound control TnT53C
IAANS (%), and the HCM mutants, TnT R92Q TnT53C
IAANS (.) and TnI S166F TnT53C
IAANS
(m) as a function of pCa. Panel C shows the Ca
2+ dependent increases in IAANS fluorescence for thin filament bound control TnT53C
IAANS (%), and the
RCM mutants, TnI D190H TnT53C
IAANS (h) and TnI R192H TnT53C
IAANS (n) as a function of pCa. Panel D shows the Ca
2+ dependent increases in IAANS
fluorescence for thin filament bound control TnT53C
IAANS (%) and ischemic related truncated TnI (1-192) TnT53C
IAANS ( ) as a function of pCa. The data sets
were normalized individually for each mutant. All TnT53C
IAANS complexes consist of the full length Tn subunits of TnC
T53C
IAANS, TnI and TnT, except for
ischemic related truncated TnI (1-192). The disease related modification is either in TnI or TnT, in either case, the other protein (TnT or TnI) was wild
type. The Ca
2+ sensitivities were reported as a dissociation constant Kd, representing a mean of three to four separate titrations 6 S.E.M.
doi:10.1371/journal.pone.0038259.g003
TnC, a Hub for the Thin Filament
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38259EGTA, 1 mM DTT, 3 mM MgCl2, 0.02% Tween-20, pH 7.0)
with constant stirring. Reconstituted thin filaments were titrated in
an identical buffer composition (excluding Tween-20). The
[Ca
2+]free was calculated using the computer program EGCA02
developed by Robertson and Potter [28]. The Ca
2+ sensitivities
were reported as a dissociation constant Kd, representing a mean
of three to four separate titrations 6 S.E.M. The data were fit with
a logistic sigmoid function (mathematically equivalent to the Hill
equation), as previously described [29].
Stopped-Flow Fluorescent Measurements
Ca
2+ exchange rates were characterized using an Applied
Photophysics model SX.20 stopped-flow instrument with a dead
time of 1.4 ms at 15uC. IAANS fluorescence was excited at
330 nm. The IAANS emission was monitored through either a
420-470 nm band-pass interference filter for TnT53C
IAANS,o ra
510 nm broad band-pass interference filter for the thin filament.
The filters were purchased from Oriel (Stratford, CT). Data traces
(an average of 3 to 5 individual traces) were fit with a single
exponential equation to calculate the kinetic rates. The working
buffer used for the kinetic measurements was 10 mM MOPS,
150 mM KCl, 1 mM DTT, 3 mM MgCl2, 0.02% Tween-20
(excluded for thin filament kinetic measurements), at pH 7.0.
10 mM EGTA was utilized to remove 200 mMC a
2+ from the Tn
complexes or thin filaments.
In order to measure the rate of Ca
2+ association to the thin
filament, a minimal concentration of EGTA was added to the thin
filament mixture to remove contaminating Ca
2+. The amount of
EGTA added was determined by steady state titrations. For the
control, TnI (1-192), TnT DK210, TnT R131W thin filaments,
5 mM EGTA was sufficient. For TnI R192H and TnI D190H thin
filaments, 10 mM EGTA was required. The observed rates at
various Ca
2+ concentrations were plotted against the Ca
2+
concentration and fit with a linear regression. The rate of Ca
2+
association to the thin filament was obtained by calculating the
slope of the fit [30]. The buffer used for the Ca
2+ association rate
measurements was the same as that used for the Ca
2+ dissociation
rate measurements.
Exposure of the Thin Filament to Artificial Ca
2+ Transients
(ACTs)
In order to determine the potential effects of altering the Ca
2+
association rate to the thin filament, the IAANS labeled TnCs on
the thin filament were exposed to artificial Ca
2+ transients (ACTs)
of increasing amplitude as previously described [19,31]. ACTs
were generated in the stopped-flow apparatus by rapidly mixing
the thin filament (at a concentration and buffer described above
for the rates of Ca
2+ dissociation) in the presence of 500 mM
EGTA (after mixing) against increasing [Ca
2+]. This technique
exposes the thin filament to rapid transient fluxes of Ca
2+ (, 1m s
half life). A relatively high concentration of EGTA (500 mM after
mixing) was utilized to ensure that the thin filament is not pre-
bound by Ca
2+ and to provide a large enough Ca
2+ sink to
effectively remove the free [Ca
2+] after mixing, effectively
generating a Ca
2+ transient. The amplitude of the Ca
2+ transient
can be adjusted by rapidly mixing the thin filament with different
amounts of Ca
2+. The ability of a Ca
2+-binding protein (in this
case, TnC on the thin filament) to respond to these rapid Ca
2+
transients, or become transiently occupied by Ca
2+, is a function of
the Ca
2+ association rate of the Ca
2+-binding protein [31]. In
order to determine the maximal response of the thin filaments to
Ca
2+, high [Ca
2+] (1 mM after mixing) was used to exceed the
[EGTA] and saturate the thin filament. Analysis of the response of
the thin filament to the ACTs is described in the legend of Figure 7.
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Statistical significance was determined by ANOVA followed by
a Dunnett’s post-hoc t-test using the statistical analysis software
Minitab (State College, PA). Two means were considered to be
significantly different when the P value was , 0.05. The data is
shown as a mean value 6 S.E.M.
Results
Effects of the Protein Modifications on the Ca
2+
Sensitivity of the Tn Complex
The data were divided into four subgroups according to the
disease subtypes to facilitate data presentation. The effects of the
disease-related protein modifications on the Ca
2+ binding prop-
erties of the Tn complex were examined since Tn is the simplest
biochemical system to test the effects of TnI and TnT
modifications on TnC. Our laboratory has developed a fluorescent
TnC, TnC
T53C
IAANS (which is specifically labeled with the fluorescent
probe IAANS on Cys 53) that minimally affects TnC function, and
reports the structural changes that occur within the regulatory
domain of TnC upon Ca
2+ binding and dissociation [11].
TnC
T53C
IAANS was incorporated into all the Tn complexes (denoted
as TnT53C
IAANS), which enabled us to follow Ca
2+ binding and
exchange with isolated or thin filament bound Tn complexes.
The Ca
2+ sensitivity of TnC within the various Tn complexes
was measured by following the Ca
2+ dependent decrease in
IAANS fluorescence. Control TnT53C
IAANS exhibited a Ca
2+ induced
half-maximal fluorescence decrease at 0.6660.03 mM (Figure 1
and Table 1). As shown in figure 1, only HCM TnI S166F
significantly increased the Ca
2+ sensitivity of the Tn complex (,
1.5-fold; Figure 1 and Table 1).
Effects of the Protein Modifications on the Rate of Ca
2+
Dissociation from the Tn Complex
Previously, we demonstrated that the fluorescence of TnT53C
IAANS
reported the actual rate of Ca
2+ dissociation from unlabeled wild
type Tn and a series of rationally engineered mutant Tn
complexes with high fidelity [11,25]. In this study, fluorescence
stopped-flow measurements were performed to determine the rate
of Ca
2+ dissociation from the disease-related TnT53C
IAANS complexes.
Figure 2 shows that the rate of Ca
2+ dissociation from control
Figure 4. Effect of disease-related protein modifications on the rate of Ca
2+ dissociation from the thin filament. Panel A shows the
time courses of the decrease in IAANS fluorescence as Ca
2+ was removed by EGTA from thin filament bound control TnT53C
IAANS, and the DCM mutants,
TnI K36Q TnT53C
IAANS, TnT R131W TnT53C
IAANS, TnT R141W TnT53C
IAANS, TnT R205L TnT53C
IAANS and TnT DK210 TnT53C
IAANS. Panel B shows the time courses of the
decrease in IAANS fluorescence as Ca
2+ was removed by EGTA from thin filament bound control TnT53C
IAANS, and the HCM mutants, TnT R92Q TnT53C
IAANS
and TnI S166F TnT53C
IAANS. Panel C shows the time courses of the decrease in IAANS fluorescence as Ca
2+ was removed by EGTA from thin filament
bound control TnT53C
IAANS, and the RCM mutants, TnI D190H TnT53C
IAANS and TnI R192H TnT53C
IAANS. Panel D shows the time courses of the decrease in IAANS
fluorescence as Ca
2+ was removed by EGTA from thin filament bound control TnT53C
IAANS and ischemic related truncated TnI (1-192) TnT53C
IAANS. All
TnT53C
IAANS complexes consist of the full length Tn subunits of TnC
T53C
IAANS, TnI and TnT, except for ischemic related truncated TnI (1-192). The disease
related modification is either in TnI or TnT, in either case, the other protein (TnT or TnI) was wild type. Data traces (an average of 3 to 5 individual
traces collected at least 10 times) were fit with a single exponential equation to calculate the kinetic rates. The data traces have been staggered and
normalized for clarity.
doi:10.1371/journal.pone.0038259.g004
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IAANS was 40.860.4/s (Table 1). Consistent with its effect on
the Ca
2+ sensitivity of Tn, HCM TnI S166F slowed the rate of
Ca
2+ dissociation ,2-fold (Figure 2 and Table 1). Besides TnI
S166F, only TnI K36Q slightly, but significantly altered the rate of
Ca
2+ dissociation from the Tn complex (, 1.2-fold faster;
Figure 2A and Table 1).
Effects of the Protein Modifications on the Ca
2+
Sensitivity of the Thin Filament
Consistent with previous studies [6,12,13], our results indicate
that the majority of the disease-related protein modifications have
no effect on the Ca
2+ binding properties of Tn. However, Tn is
part of the thin filament system. Accordingly, we examined the
effects of TnI and TnT modifications on the Ca
2+ binding
properties of the reconstituted thin filament.
Thin filament bound control TnT53C
IAANS exhibited a Ca
2+-
dependent half-maximal fluorescence increase at 4.560.2 mM
(Figure 3 and Table 2). Consistent with the general Ca
2+
desensitizing effects of DCM mutations [5,13], all five DCM
mutations studied here desensitized Ca
2+ binding to the thin
filament. TnT R131W, R141W and R205L slightly desensitized
Ca
2+ binding to the thin filament by , 1.5 fold; TnI K36Q had an
intermediate Ca
2+ desensitizing effect of , 2-fold; while TnT
DK210 had the largest Ca
2+ desensitizing effect of , 3.5-fold
(Figure 3C and Table 2). Of the Ca
2+ desensitizing modifications,
only TnT DK210 significantly decreased the Ca
2+ binding
cooperativity of the thin filament by , 1.3-fold (Figure 3C and
Table 2).
Consistent with the general Ca
2+ sensitizing effect of HCM,
RCM and ischemia-induced truncation of TnI [5,6], four of the
five TnI and TnT modifications studied here sensitized Ca
2+
binding to the thin filament. As shown in figure 3B, HCM TnI
S166F slightly, but significantly sensitized Ca
2+ binding to the thin
filament by , 1.4-fold. However, the other HCM mutation R92Q
did not significantly alter thin filament Ca
2+ sensitivity, but
significantly decreased the Ca
2+ binding cooperativity of the thin
filament by , 1.3-fold (Figure 3B and Table 2).
Figure 3C shows that both RCM mutations, TnI D190H and
TnI R192H, increased the Ca
2+ sensitivity of the thin filament by
, 2.8-fold (Figure 3C and Table 2). Compared to the HCM and
RCM mutations, which had slight and intermediate Ca
2+
sensitizing effects, the ischemia-induced truncation of TnI (1-
192) hyper-sensitized Ca
2+ binding to thin filament by , 6.3-fold
(Figure 3D and Table 2).
Effect of the Protein Modifications on the Rate of Ca
2+
Dissociation from the Thin Filament
It is generally assumed that a change in the Ca
2+ sensitivity of
TnC is due to a change in the rate of Ca
2+ dissociation. Figure 4A
shows that the rate of Ca
2+ dissociation from thin filament bound
control TnT53C
IAANS was 109.760.7/s (Table 2). Figure 4A also shows
the effects of the five DCM mutations on the rate of Ca
2+
dissociation from the thin filament. TnT R141W negligibly altered
the rate of Ca
2+ dissociation, while TnT R131W and R205L
caused a slightly faster rate of Ca
2+ dissociation from the thin
filament (less than , 1.5-fold; Figure 4A and Table 2). TnI K36Q
and TnT DK210 had larger effects on accelerating the rate of
Ca
2+ dissociation from the thin filament (, 2.5-fold and , 2.3-
fold, respectively; Table 2).
Figure 4B, C and D show the effects of the two HCM
mutations, two RCM mutations and ischemia-induced truncation
of TnI on the rate of Ca
2+ dissociation from the thin filament. The
HCM mutation TnI S166F slowed the rate of Ca
2+ dissociation by
, 1.7-fold, while the HCM mutation TnT R92Q had no effect on
the dissociation rate (Figure 4B and Table 2). Both RCM
mutations slowed the rate of Ca
2+ dissociation from the thin
filament, ,1.2-fold slower for TnI D190H and ,1.5-fold slower
for TnI R192H (Figure 4C and Table 2). The ischemia-induced
truncation of TnI (1-192) slowed the rate of Ca
2+ dissociation from
the thin filament by , 2-fold (Figure 4D and Table 2).
Effects of the Protein Modifications on the Rate of Ca
2+
Association to the Thin Filament
The kinetic studies indicate that the changes in Ca
2+ sensitivity
of the thin filament caused by the protein modifications are in part
due to changes in the rate of Ca
2+ dissociation. However, as shown
in table 2 and figure 5, there was only a weak correlation
(r
2=0.17, fit not shown) between the changes in the thin filament
Ca
2+ sensitivities and the changes in the Ca
2+ dissociation rates for
the different protein modifications. These results suggest that the
rate of Ca
2+ association to the thin filament can also be altered by
the protein modifications. To test this hypothesis, stopped-flow
experiments were performed to measure the rate of Ca
2+
association to the thin filaments containing TnI R192H,
D190H, TnI (1-192), TnT DK210 and TnT R131W. Based on
the calculated rate of Ca
2+ association, TnT R131W was predicted
to have little effect on the rate of Ca
2+ association while the rest of
the protein modifications were expected to significantly change the
rate of Ca
2+ association (Table 2). Using a traditional approach to
determine the apparent Ca
2+ association rate to the thin filament,
the measured rate of Ca
2+ association to the control thin filament
was 961610
6 M
21s
21 (Figure 6A, 6C and Table 2). Consistent
with the calculated Ca
2+ association rates, TnI R192H, D190H
and TnI (1-192) increased the apparent rate of Ca
2+ association to
the thin filament by , 4- to 5-fold (Figure 6B, 6D and Table 2). In
contrast, TnT DK210 slowed the apparent rate of Ca
2+
association to the thin filament by ,3-fold (Figure 6D and
Table 2). On the other hand, the apparent rate of Ca
2+ association
to the thin filament containing TnT R131W was similar to that of
the control thin filament, with the rate being 1261610
6 M
21s
21
Figure 5. The relationship between changes in the Ca
2+
sensitivity and the rate of Ca
2+ dissociation. The changes in the
thin filament Ca
2+ sensitivity for the ten disease-related protein
modifications are plotted against the changes in the rate of Ca
2+
dissociation from the thin filament. The straight line in the figure
represents a perfect correlation between the thin filament change in
Ca
2+ sensitivity and Ca
2+ dissociation rate.
doi:10.1371/journal.pone.0038259.g005
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that the apparent rate of Ca
2+ association to the thin filament can
also be altered by the disease-related protein modifications.
The Ca
2+ association rate data suggest that the disease-related
modifications alter the ability of the thin filament to respond to a
Ca
2+ transient. This idea was tested in a stopped-flow apparatus by
exposing the thin filament to artificial Ca
2+ transients (ACTs) of
increasing amplitude (Figure 7). Due to the relatively slow Ca
2+
association rate of EGTA, initially Ca
2+ transiently binds to the
thin filament (dependent on its Ca
2+ association rate) until EGTA
chelates the Ca
2+ (, 1 ms half life). Although these are not
physiological Ca
2+ transients, it is expected that for a fixed Ca
2+
transient amplitude, a faster rate of Ca
2+ association should lead to
a higher level of transient occupancy, while a slower rate of Ca
2+
association should lead to a lower level of transient occupancy.
Figure 7A shows the responses of thin filament bound control
TnT53C
IAANS to ACTs. As the [Ca
2+] was successively increased from
12.5 mMt o2 5 mM and then to 50 mM (after mixing), the
percentage of transient occupancy increased from 1761%, to
3062% and then to 4763%, respectively (Table 3). Compared to
the control thin filament, the percentage of the transient
occupancy was higher for TnI (1-192) and lower for TnT
DK210 at all three Ca
2+ concentrations (Figure 7B, 7C and
Table 3). Thus, consistent with the Ca
2+ association rate
calculations and measurements, the ACT experiments support
the idea that the TnI (1-192) containing thin filament has an
apparent faster rate of Ca
2+ association, while the TnT DK210
containing thin filament has an apparent slower rate of Ca
2+
association than the control thin filament.
Discussion
In this study, we examined the effects of cardiac disease-related
TnI and TnT modifications on the Ca
2+ binding properties of
TnC in the Tn complex and on the thin filament. The selected ten
protein modifications are associated with a broad range of cardiac
diseases: three subtypes of familial cardiomyopathies (DCM,
HCM and RCM), and ischemia-reperfusion injury. Most of the
selected protein modifications have previously been shown to alter
Figure 6. Effect of disease-related protein modifications on the rate of Ca
2+ association to the thin filament. Panel A shows the kinetic
traces (an average of 3 to 5 individual traces collected at least 9 times) observed for Ca
2+ association to thin filament bound control TnT53C
IAANS at 5 mM,
10 mM and 20 mMC a
2+ ([Ca
2+] after mixing). Panel B shows the kinetic traces (an average of 3 to 5 individual traces collected at least 9 times)
observed for Ca
2+ association to thin filament bound TnI(1-192) TnT53C
IAANS at 2.5 mM, 5 mM and 10 mMC a
2+. The rate of the fluorescence increase when
Ca
2+ associates with the thin filament was fit with a single exponential to calculate the observed rate (kobserved). All TnT53C
IAANS complexes consist of the
full length Tn subunits of TnC
T53C
IAANS, TnI and TnT, except for ischemic related truncated TnI (1-192). The disease related modification is either in TnI or
TnT, in either case, the other protein (TnT or TnI) was wild type. Panel C shows the plots of kobserved versus [Ca
2+] for thin filament bound control
TnT53C
IAANS (%) and TnI (1-192) TnT53C
IAANS ( ). The rate of Ca
2+ association to the thin filament was obtained by calculating the slope of a linear fit to the
data. Panel D shows the plots of kobserved versus [Ca
2+] for thin filament bound TnI R192H TnT53C
IAANS (n), TnI D190H TnT53C
IAANS (h), TnT DK210 TnT53C
IAANS
(q), and TnT R131W TnT53C
IAANS (#).
doi:10.1371/journal.pone.0038259.g006
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2+ sensitivity of skinned cardiac muscle force generation,
and/or the actomyosin-ATPase activity [12,13,21,22]. Transgenic
mice models have been developed for TnI R192H, TnI (1-192),
TnT R92Q, TnT DK210 and TnT R141W, all of which
recapitulate the phenotypes of the human diseases
[23,24,32,33,34]. In addition to altering the steady-state Ca
2+
sensitivity of force generation, some of these protein modifications
also alter the kinetics and magnitude of contraction and/or
relaxation [23,24]. Thus, it is important to understand not only the
effects of these protein modifications on the Ca
2+ sensitivity of
TnC, but also the effects on the kinetics of Ca
2+ exchange with
TnC.
Previous studies utilized IAANS labeled fluorescent TnCs (at
either Cys 35 or Cys 84) to measure the effects of disease-related
protein modifications on the steady-state Ca
2+ sensitivity of TnC
[6,12,13,22]. Our steady-state results were qualitatively consistent
with these previous studies. For instance, we observed that the
majority of the disease-related protein modifications did not alter
the Ca
2+ binding properties of the Tn complex [6,12,13,22].
However, when reconstituted into the thin filament, the DCM
mutations decreased the Ca
2+ sensitivity of the thin filament, while
most of the HCM and RCM mutations, as well as the ischemia-
induced truncation of TnI, increased the Ca
2+ sensitivity of the
thin filament [6,12,13,22]. Slight quantitative differences in
the Ca
2+ sensitivity observed for the same protein modifications
in the current study, compared to previous studies [6,12,13,22],
might be due to the utilization of different fluorescent TnCs,
protein isoforms from different species (human in this manuscript),
buffer composition, temperature, or the integrity of the Tn
complex and/or the reconstituted thin filament. Great care was
taken in the current study to ensure that there was no
contaminating free TnC within the Tn complex, or free Tn
within the thin filament that would have compromised the results.
The steady-state Ca
2+ sensitivity of TnC is determined by the
kinetics of Ca
2+ association and dissociation. It is generally
assumed that alterations in the steady-state Ca
2+ sensitivity of TnC
operate exclusively through changes in the rate of Ca
2+
dissociation, since Ca
2+ association to TnC has been traditionally
thought to be diffusion controlled (for review see [15]). Our data
clearly indicate that the majority of the disease-related protein
modifications altered the rate of Ca
2+ dissociation from the thin
filament, in a way that is consistent with their effect on Ca
2+
sensitivity. However, the magnitude of the change in the Ca
2+
dissociation rates does not always correlate with the magnitude of
the Ca
2+ sensitivity changes. This finding suggests that the Ca
2+
association rate to TnC must also be affected by the disease-related
protein modifications. Experimental measurements verified that
the apparent rates of Ca
2+ association were also altered by some of
the disease-related protein modifications. These data are consis-
tent with our previous results that demonstrated natural and
engineered TnC mutations could also affect the rate of Ca
association to TnC [19,20]. Interestingly, the Ca
2+ sensitizing
protein modifications (TnI R192H, D190H, and ischemia-induced
truncation of TnI) tend to alter the Ca
2+ binding sensitivity by
modulating both the association and dissociation rates; while the
Ca
2+ desensitizing mutations tend to predominantly affect the
dissociation rates (with the exception of TnT DK210).
While the physiological significance of the Ca
2+ dissociation rate
from TnC remains controversial [15], it is striking that Tn
modifications (disease or engineered) with slowed or accelerated
Ca
2+ dissociation rates prolonged or abbreviated relaxation
[23,24,35]. Thus, an aberrant rate of Ca
2+ dissociation from
TnC could potentially contribute to the diastolic dysfunction
typically observed with the various cardiomyopathies [36,37]. On
Figure 7. Response of disease-related protein modifications to
ACTs with increasing amplitude. Panels A, B and C show responses
of thin filament bound control TnT53C
IAANS, TnI (1-192) TnT53C
IAANS and TnT
nK210 TnT53C
IAANS to ACTs, respectively. The peak transient occupancy
was determined at ,3 ms for each sub-saturating [Ca
2+]. 100%
occupancy was determined at the plateau of the trace in which
saturating Ca
2+ (1000 mM after mixing) was rapidly mixed with the thin
filament. 0% occupancy was determined by mixing the thin filament
without Ca
2+ (data not shown). Each transient occupancy calculation
was an average of three separate experiments repeated twice, with
each trace being an average of at least 5 separate traces. The 25 mM
Ca
2+ data for TnT nK210 is not shown for clarity. All TnT53C
IAANS complexes
consist of the full length Tn subunits of TnCT53C
IAANS, TnI and TnT, except
for ischemic related truncated TnI (1-192). The disease related
modification is either in TnI or TnT, in either case, the other protein
(TnT or TnI) was wild type.
doi:10.1371/journal.pone.0038259.g007
TnC, a Hub for the Thin Filament
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38259the other hand, the rate of Ca
2+ association to the thin filament
could affect the amount of maximal force generation or myocyte
shortening. For instance, despite similar intracellular Ca
2+
transients, myocytes transfected with TnI R192H had a larger
shortening amplitude than control myocytes, especially under high
stimulating frequencies [38]. Whereas, intact papillary muscles
from TnT DK210 transgenic mice displayed the same amount of
maximal force as control muscles, even though the amplitude of
the intracellular Ca
2+ transient was higher than that of the control
[24]. These transgenic studies suggest that in addition to the
intracellular Ca
2+ transient, the response of the thin filament to
Ca
2+ may also regulate the extent and duration of force
development. Consistent with this idea, the current study
demonstrates that both TnI (1-192) and TnT DK210 altered the
response of the thin filament to non-physiological, artificial Ca
2+
transients in a way consistent with their contractile effects.
There are potentially multiple mechanisms that exist to alter the
Ca
2+ binding properties of TnC on the thin filament [15]. It is well
established that the binding of TnI to TnC is critical in
determining the Ca
2+ sensitivity and kinetics of TnC [11,15].
However, it appears that only TnI S166F altered the ability of TnI
to directly change the Ca
2+ binding properties of TnC, since it was
the only protein modification that substantially altered the Ca
2+
binding properties of the Tn complex. TnI S166F is located close
to the switch region of TnI that binds to the hydrophobic pocket of
the regulatory domain of TnC. Thus, TnI S166F might be
influencing this critical TnC-TnI interaction to affect the Ca
2+
binding properties of TnC.
The more distant C-terminal region of TnI (residues 188-210) is
believed to contribute to the inhibition of actomyosin interactions
during diastole by direct interactions with actin-Tm [39]. The
ability of TnI to bind actin-Tm may reduce the ability of the
switch region of TnI to interact with the hydrophobic pocket of
TnC, in essence reducing the apparent Ca
2+ sensitivity of TnC
[11]. TnI D190H, R192H and the removed residues from TnI (1-
192) are located within this region of TnI and may weaken the
interactions between TnI and actin-Tm. In this regard, these
protein modifications may facilitate the switching of TnI from
actin-Tm to TnC, causing an enhanced apparent sensitivity for
Ca
2+ only when the Tn complex is incorporated in the thin
filament. Similarly, the TnT mutations may also change the ability
of TnI to bind to actin-Tm. This hypothesis would be consistent
with the TnT modifications only affecting the apparent Ca
2+
sensitivity of the thin filament and not the Tn complex.
In summary, the disease-related protein modifications studied in
this work adversely altered the steady-state Ca
2+ sensitivity of the
thin filament by influencing both the association and dissociation
rates of Ca
2+ exchange. The protein modifications modified the
Ca
2+ exchange properties of TnC in a way consistent with their
effect on cardiac muscle physiology. Therefore, TnC may act as a
central hub that converges these pathological stimuli to affect
cardiac contractile properties. The abnormal myofilament Ca
2+
binding along with aberrant intra-cellular Ca
2+ signaling could
contribute to contractile dysfunctions leading to cardiac remod-
eling and disease phenotypes. Thus, pharmaceutically [40] or
genetically targeting TnC to correct the abnormal myofilament
Ca
2+ binding properties may represent a beneficial therapeutic
strategy.
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